JP2020503001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503001A5 JP2020503001A5 JP2019526515A JP2019526515A JP2020503001A5 JP 2020503001 A5 JP2020503001 A5 JP 2020503001A5 JP 2019526515 A JP2019526515 A JP 2019526515A JP 2019526515 A JP2019526515 A JP 2019526515A JP 2020503001 A5 JP2020503001 A5 JP 2020503001A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid sequences
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 50
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 102000048362 human PDCD1 Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000004073 interleukin-2 production Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- -1 vaccines Substances 0.000 claims 1
- 238000013389 whole blood assay Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424163P | 2016-11-18 | 2016-11-18 | |
| US62/424,163 | 2016-11-18 | ||
| PCT/EP2017/079615 WO2018091661A1 (en) | 2016-11-18 | 2017-11-17 | Anti-pd-1 antibodies and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503001A JP2020503001A (ja) | 2020-01-30 |
| JP2020503001A5 true JP2020503001A5 (enExample) | 2021-01-07 |
| JP7178999B2 JP7178999B2 (ja) | 2022-11-28 |
Family
ID=60484347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526515A Active JP7178999B2 (ja) | 2016-11-18 | 2017-11-17 | 抗ｐｄ－１抗体および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11359018B2 (enExample) |
| EP (1) | EP3541841B1 (enExample) |
| JP (1) | JP7178999B2 (enExample) |
| CN (1) | CN110214153B (enExample) |
| AU (1) | AU2017361868B2 (enExample) |
| CA (1) | CA3043141A1 (enExample) |
| DK (1) | DK3541841T3 (enExample) |
| EA (1) | EA201991214A1 (enExample) |
| ES (1) | ES2991086T3 (enExample) |
| PH (1) | PH12019500923A1 (enExample) |
| TW (1) | TWI780083B (enExample) |
| WO (1) | WO2018091661A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| US10501543B2 (en) | 2016-10-14 | 2019-12-10 | Xencor, Inc. | IL15/IL15Rα heterodimeric Fc-fusion proteins |
| CN114984209B (zh) | 2017-04-05 | 2025-08-29 | 正大天晴药业集团股份有限公司 | 靶向pd-1、tim-3及lag-3的组合疗法 |
| CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
| EP3781596A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| WO2019204655A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| AU2019343131A1 (en) * | 2018-09-17 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB2 antibodies and methods of use thereof |
| CN113544144A (zh) | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| CN113423734A (zh) | 2018-10-12 | 2021-09-21 | Xencor股份有限公司 | 靶向PD-1的IL-15/IL-15RαFC融合蛋白及其在联合疗法中的应用 |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| EP3929214A4 (en) * | 2019-05-30 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2 |
| TWI889320B (zh) | 2019-07-05 | 2025-07-01 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CA3176606A1 (en) * | 2020-03-26 | 2021-09-30 | Cureimmune Therapeutics Inc. | Anti-pd-1 antibodies and methods of use |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| CN112812179B (zh) * | 2021-01-19 | 2022-07-22 | 北京大学 | 高亲和力高特异性抗cmtm6单克隆抗体及其用途 |
| CN115368456B (zh) * | 2021-05-18 | 2025-09-23 | 苏州鑫康合生物医药科技有限公司 | 抗pd-1多肽及其用途 |
| JP2024518844A (ja) | 2021-05-20 | 2024-05-07 | ダイアンサス セラピューティクス オプコ， インコーポレイテッド | Ｃ１ｓに結合する抗体およびその使用 |
| WO2023235666A2 (en) * | 2022-05-31 | 2023-12-07 | Vanderbilt University | Human antibodies to bordetella pertussis and uses therefor |
| WO2024112734A1 (en) * | 2022-11-21 | 2024-05-30 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to c1s and uses thereof |
| WO2024233251A2 (en) * | 2023-05-05 | 2024-11-14 | The Johns Hopkins University | Human monoclonal antibodies that enhance pad4 for use in autoimmune diseases |
| WO2025137473A1 (en) * | 2023-12-20 | 2025-06-26 | Dianthus Therapeutics Opco, Inc. | Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP4361545B2 (ja) * | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| JP2010500984A (ja) | 2006-08-17 | 2010-01-14 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｃｒ５に対する抗体と抗膜融合ペプチドとの抱合体 |
| BRPI0808171A2 (pt) | 2007-03-01 | 2014-08-05 | Symphogen As | Método para clonagem de anticorpos cognatos |
| NZ582150A (en) * | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| HRP20221262T1 (hr) * | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
| DK3508502T5 (da) | 2013-09-20 | 2024-09-02 | Bristol Myers Squibb Co | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| KR102524920B1 (ko) * | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| PL3368572T3 (pl) | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| HUE053452T2 (hu) | 2016-05-18 | 2021-07-28 | Boehringer Ingelheim Int | Anti-PD-1 és anti-LAG3 antitestek rák kezelésére |
-
2017
- 2017-11-17 EA EA201991214A patent/EA201991214A1/ru unknown
- 2017-11-17 DK DK17805146.2T patent/DK3541841T3/da active
- 2017-11-17 ES ES17805146T patent/ES2991086T3/es active Active
- 2017-11-17 CA CA3043141A patent/CA3043141A1/en active Pending
- 2017-11-17 TW TW106139948A patent/TWI780083B/zh active
- 2017-11-17 JP JP2019526515A patent/JP7178999B2/ja active Active
- 2017-11-17 US US16/461,957 patent/US11359018B2/en active Active
- 2017-11-17 EP EP17805146.2A patent/EP3541841B1/en active Active
- 2017-11-17 AU AU2017361868A patent/AU2017361868B2/en active Active
- 2017-11-17 CN CN201780071687.XA patent/CN110214153B/zh active Active
- 2017-11-17 WO PCT/EP2017/079615 patent/WO2018091661A1/en not_active Ceased
-
2019
- 2019-04-24 PH PH12019500923A patent/PH12019500923A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503001A5 (enExample) | ||
| EP3341020B1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| JP6779299B2 (ja) | 抗ｐｄ−ｌ１抗体およびその使用 | |
| EP3334824B1 (en) | Pd-1 antibodies | |
| JP6953612B2 (ja) | チェックポイントインヒビター二重特異性抗体 | |
| JP2018529359A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| JP7352973B2 (ja) | 二重特異性抗体及びその使用 | |
| JP2019519199A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| RU2019113790A (ru) | Анти-lag-3 антитела и их композиции | |
| HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
| JP2021508255A5 (enExample) | ||
| JP2023071889A (ja) | Ｔｉｇｉｔおよびｐｄ－１／ｔｉｇｉｔ結合分子 | |
| EA034854B1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP2017529838A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2013520984A5 (enExample) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2015503909A5 (enExample) | ||
| JP2017534259A5 (enExample) | ||
| JP2020502038A (ja) | Ｐｄ−１抗体 | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2017521054A5 (enExample) | ||
| US20210292416A1 (en) | Bispecific antibodies targeting immune checkpoints |